Most therapeutic antibodies have been produced in mammalian cells, such as Chinese Hamster Ovary (CHO) cells. Recently, cell-free protein synthesis has emerged as a promising production strategy to accelerate the development and manufacturing of therapeutic antibodies and other biologics.
Cell-free protein synthesis can produce functional therapeutic antibodies from linear or plasmid DNA templates in less than 24 h with volumetric productivities and scales competitive with CHO-cell production.
Antibody development generally begins by generating many lead molecules by immunization, phage display, ribosome display, etc. To know more about antibody production, you can also browse https://www.bosterbio.com/featured-products.
Image Source: Google
These “pooled” techniques can narrow down leads to 100s to 1000s, but the sample requirements of analytical techniques are such that evaluating the ability of a specific sequence to be developed into a drug (often called “developability”) eventually requires the generation of preparative amounts of each defined antibody in a well-by-well screen.
Generally, all antibody formats require the proper post-translational formation of disulfide bonds. Depending on their mechanism of action, some antibodies require glycosylation to engage the immune system while others only need to bind to their target.
Glycosylation allows antibodies to recruit immune cells (usually Natural Killer cells) to kill the cells they bind to (a process known as Antibody-Dependent Cellular Cytotoxicity). However, glycosylation is not required for target binding or half-life extension.
Most essays that do not involve NK cell engagement will not require glycosylation on the antibody. Due to the heterogeneity generated by many different glycoforms and its ramifications for drug development, developers will generally avoid glycosylation unless it is necessary.